Trials / Sponsors / Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc.
Industry · 4 registered clinical trials — 1 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Ritux Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc) | Phase 2 | 2025-07-09 |
| Active Not Recruiting | AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nep Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Refractory Systemic Lupus Erythematosus | Phase 1 | 2024-04-03 |
| Withdrawn | A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors Breast Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 1 / Phase 2 | 2023-08-01 |
| Completed | AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Non Hodgkin Lymphoma | Phase 1 / Phase 2 | 2021-03-29 |